UKUK

New biotech park in Scotland

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture between BioCity Nottingham and Roslin BioCentre, announced the acquisition of the 23 acre site at Newhouse in Lanarkshire. It was closed last year as part of Merck Inc’s global R&D downsizing. It comprises 130,000 sq ft of purpose built laboratories and office space and is located between the city centres of Glasgow and Edinburgh. "BioCity Nottingham’s success in nurturing and growing over 70 new companies since 2003, and Roslin’s expertise in life sciences innovation and facilities management makes this team the perfect commercial partnership", said Louis J. Nisbet, Chairman of BioCity Scotland. The site has already signed up its first two tenants, and hopes to create as many as 500 jobs at the location. A total of 250 jobs were lost after Merck (known as Merck Sharp & Dohme in Europe) announced its closure in July 2010.

UKUK

14.11.2011

London – GlaxoSmithKline goes west. The British pharmaceutical company launched the $50-million GSK Canada Life Sciences Innovation Fund that will invest in “early-stage breakthrough research” in health care life science in...

UKUK

04.10.2011

Heidelberg/Cambridge/London– A team of researchers from GlaxoSmithKline, the biotech company Cellzome and from Universities Cambridge, Ulm and Amsterdam have found a promising treatment for mixed lineage (MLL-fusion) leukaemia...

UKUK

01.10.2011

Amersham – GE Healthcare intends to remain a major force in cancer therapy. Based in London, the health business of the US technology giant announced it will be reserving €730m of its total R&D budget over the next five years for...

UKUK

01.10.2011

Wolverhampton – One of the challenges for manufacturers of probiotic foods is getting large enough numbers of the bacteria into the intestines; most perish under the strongly acidic conditions in the stomach. Scientists from the...

UKUK

01.10.2011

Washington – British Shire plc gained more than 10% in late August on the London Stock Exchange after the US FDA approved Firazyr (icatibant) for acute attacks of hereditary angioedema. The compound was developed by Berlin-based...

UKUK

26.09.2011

London – The first clinical trial using human embryonic stem cells will be carried out at the Moorfields Eye hospital in London. Doctors will inject retinal cells into the eyes of 12 patients with Stargardt‘s macular dystrophy, a...

UKUK

20.09.2011

Amersham – GE Healthcare intends to stay a major force in cancer. The health business of the US-technological company, which is based in London, announced to reserve €730m of its total R&D budget over the next five years for...

UKUK

29.08.2011

Cambridge - A new biotech spin off from the University of Cambridge launched with €6.8m venture capital. Newco Mission Therapeutics Ltd. plans to develop cancer drugs targeting enzymes in ubiquitin pathways that control cellular...

UKUK

23.08.2011

London - GlaxoSmithKline has invested about €1.5m to take a 25.4 percent stake in Autifony Therapeutics, a British biotechnology company spun out of GSK to research treatments for tinnitus and hearing loss. Autifony’s other...

Displaying results 21 to 30 out of 396

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/2/article/new-biotech-park-in-scotland.html

Product of the week

Products

Events

All Events

Current issue

All issues